Our results demonstrate that the CD4/CD8 ratio and CD19+ cell counts were higher in the PR+CR group than in the SD group, suggesting that stronger immune status predicts the short-term efficacy of prostate cancer patients treated with carbon ions. The gene discussed is CD4; the disease is prostate carcinoma.